New combo attack on stomach cancer before surgery
NCT ID NCT03776487
Summary
This study is testing a new treatment approach for patients with stomach or gastroesophageal cancer that can be surgically removed. It combines two immunotherapy drugs (nivolumab and ipilimumab) with chemotherapy and radiation before surgery, aiming to shrink the tumor and help the immune system fight the cancer. The main goals are to see if this combination is safe and effective for 32 participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLINICAL STAGE III GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.